With the FDA now holding public workshops on how a generic GLP-1 drug pathway might eventually work, it's worth separating the scientific question from a more concrete one: even if the manufacturing and testing challenges were solved tomorrow, how long would legal protections keep generic semaglutide and tirzepatide off the market anyway? Based on currently listed U.S. patents, the answer is measured in years, in some cases well over a decade.

Semaglutide's Patent Timeline

Novo Nordisk's compound patent covering semaglutide itself, the active ingredient in Ozempic and Wegovy, is currently listed as running through December 5, 2031. Additional formulation and dosage-strength patents extend further: certain Ozempic strengths are listed through June 2033, and patents covering the standard and high-dose Wegovy formulations run through February 17, 2041. Patents covering oral semaglutide formulations are listed through February 1, 2039. These are patent-record dates, not launch dates, and some listed patents can be narrowed or invalidated through litigation before they expire.

Tirzepatide's Patent Timeline

Eli Lilly's compound patent on tirzepatide, the active ingredient in Mounjaro and Zepbound, is currently listed as running through May 13, 2036. Additional patents covering specific Mounjaro formulations extend to December 2041, and Zepbound-specific formulation patents are listed through July 2039. As with semaglutide, generic drugmakers have already begun challenging some of these patents: litigation over tirzepatide's patents began August 6, 2026, with a court deadline set for November 13, 2029, part of the standard legal process that can shorten, but does not automatically shorten, a patent's effective life.

Patents Are Only One of Four Barriers

Patent expiration is necessary but not sufficient for a generic to reach the market. Separately from patents, the FDA can grant regulatory exclusivity periods that block generic approval on their own timeline, independent of when the underlying patents expire, meaning exclusivity can outlast a patent or, in some cases, expire before it. Patent litigation itself adds a third layer: when a generic manufacturer challenges a brand-name patent under the "Paragraph IV" process, it can trigger an automatic 30-month stay on FDA approval of the generic while the litigation plays out, regardless of the patent's listed expiration date. Finally, even after legal and regulatory barriers clear, a generic manufacturer still has to build out the actual complex manufacturing and device supply chain described in the FDA's generic GLP-1 workshop, which takes real time and investment on its own.

A Useful International Comparison

Canada offers a preview of how these layers can interact in practice: a generic semaglutide product became available there after the underlying active-ingredient patent had already expired, but only once Health Canada's own separate data-protection period, unrelated to the patent itself, also ran out on January 4, 2026. The same multi-layered pattern is likely to play out in the U.S. market, just on its own separate timeline for each type of protection.

What This Means for Compounded Alternatives

It's worth being clear that compounded semaglutide and tirzepatide, which briefly proliferated during the 2022-2024 supply shortage covered elsewhere on this site, are a legally distinct situation from generics and were never a patent workaround; they relied on a separate shortage-related compounding exemption that has since been narrowed as supply stabilized. A lawful generic, once one exists, will be a different thing entirely: an FDA-approved product that has cleared patent, exclusivity, and manufacturing hurdles all at once, which based on the timelines above remains a multi-year proposition even in the most optimistic scenario.